Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobomarsen in various lymphomas and leukemias
NCT02580552Phase 1Completed
- Sponsor
- Viridian Therapeutics
- Start
- Feb 2016
- Primary completion
- Oct 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of cobomarsen in cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and 1 more (6 arms), sponsored by Viridian Therapeutics. Primary endpoint: Safety and tolerability of cobomarsen. Started Feb 2016; status: completed.
02
Drugs
cobomarsen
03
Conditions
cutaneous T-cell lymphoma (CTCL)chronic lymphocytic leukemia (CLL)diffuse large B-cell lymphoma (DLBCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT02580552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580552.